We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

8 hedge funds and large institutions have $333K invested in ABVC BioPharma in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

159% more capital invested

Capital invested by funds: $129K → $333K (+$204K)

1.36% more ownership

Funds ownership: 1.05% → 2.41% (+1.4%)

0% more funds holding

Funds holding: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CIC
Chase Investment Counsel
Virginia
+$231K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$25.5K
3
Bank of America
Bank of America
North Carolina
+$5.75K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.27K
5
TRCT
Tower Research Capital (TRC)
New York
+$2.52K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$42K
2
Citadel Advisors
Citadel Advisors
Florida
-$31.5K

ABVC Hedge Fund Activity: Q1 2024 in Review

8 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q1 2024, worth a combined $333K — up 159% from $129K a quarter earlier.

Fund positioning in ABVC was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 0 trimmed.

The largest buyer was Chase Investment Counsel, opening a new position worth an estimated $231K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $42K sold.

  • 8 institutional investors held ABVC BioPharma (ABVC) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $333K of ABVC BioPharma stock for Q1 2024, up 159% quarter-over-quarter.
  • 2 funds opened new ABVC BioPharma positions in Q1 2024 and 2 closed out, a net change of 0 holders.
  • The largest ABVC BioPharma buyer in Q1 2024 was Chase Investment Counsel, an estimated $231K added.
  • The largest ABVC BioPharma seller in Q1 2024 was Renaissance Technologies, an estimated $42K sold.

Based on aggregated 13F filings for Q1 2024.